Overview

QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Status:
Withdrawn
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.
Details
Lead Sponsor:
Bayer
Treatments:
Interferon beta-1b
Interferon-beta
Interferons